



# Moving healthcare forward, together

Anticipating your needs before they arise is how we help you stay ahead. For more than 125 years, BD has known one thing to be true—for healthcare professionals to be at their best, they need the best. That's why we're continually envisioning the solutions of tomorrow by innovating today.

Visit **bd.com** to learn more.



## **WELCOME** TO THE 2025 UTAH LIFE SCIENCES SUMMIT





On behalf of BioUtah, we welcome you to the 2025 Utah Life Sciences Summit, now in its 16th year of bringing the industry together to network, learn, and exchange ideas. As we try to do every year, the content of this event is targeted to address relevant topics that inform, educate, and showcase the life sciences in the State of Utah. This year, we have a smorgasbord of content. There is something for everyone who attends. You will notice a forward-looking theme for virtually every presentation or panel. Al is a recurring topic as it is affecting every aspect of life sciences. Workforce and regulatory presentations will also examine what comes next, not just what is.

We are fortunate to once again host a town hall meeting with the Director of FDA's Center for Devices and Radiological Health, Dr. Michelle Tarver. Dr. Tarver will respond to questions you may have. We are looking forward to hearing from Jeff Moss, head of the Governor's Office of Economic Opportunity, who will discuss the Nucleus Institute and how it supports our industry. Cambridge Fellow, Dr. Carter Dredge, who heads up the Intermountain Health Institute, will provide very forward-looking remarks about health care delivery. Dr. Peter Marks, former CBER Director at FDA and now with Eli Lilly, will examine the emergence of new therapeutics and what he perceives is the future for such therapies.

Utah's own Melissa Holyoak, one of five commissioners of the Federal Trade Commission, will hold a fireside chat with BioUtah Legal Counsel, Jacey Skinner, about topics affecting our industry. Also participating in the morning session will be Mayealie Adams, Danaher's VP of Government Affairs, who will interview Michelle Rozo, Vice Chair of the National Security Commission on Emerging Biotechnology (NSCEB). The NSCEB was established by Congress several years ago to make recommendations for policy changes to ensure the United States maintains its worldwide leadership in life sciences. Finally, Bob Carter, CEO of University of Utah Health, and Mark Ott, Dean of the BYU medical school, will be interviewed by Dr. David Bearss for his Good Medicine podcast about providing health care in a world of changing demographics.

Interspersed between morning presentations, we will present the 2025 BioUtah Industry Awards to some very deserving industry leaders. Join us in honoring them! Our four afternoon track sessions are designed to cover a broad range of topics, including regulatory and quality, workforce, AI, social media, product marketing, and legal and compliance challenges. If you find you want to be in two places at one time, don't fret. We will tape all sessions and make them available to attendees following the Summit.

We also welcome to the Summit a contingency from Korea led by the Korean Health Industry Development Institute, who will be accompanied by four Korean life sciences companies exploring the U.S. market. The Institute is sponsoring our closing reception at which an MOU will be signed with BioUtah, World Trade Center Utah, and the Governor's Office of Economic Opportunity.

We appreciate the generous support of all our sponsors who have made the Summit possible. Special thanks to the firm of Mayer Brown, who has stepped up for the fourth consecutive year as our Title Sponsor. Please enjoy the Summit and look for our follow-up survey so you can provide feedback to help us make future Summits even better. Thanks for joining us.

Kelvyn Cullimore
Kelvyn Cullimore, Jr.

Kelvyn Cullimore, Jr. President & CEO, BioUtah

### **EVENT SPONSORS**

### MAYER BROWN TITLE

**PREMIERE** 



**OPENING** 









**AWARDS** 

SUPPORTING











### TRACK SESSIONS









CONTRIBUTING

Johnson Johnson

J.P.Morgan





WI-FI



**LANYARD** 





# INNOVATIVE CONSTRUCTION FOR UTAH'S LIFE SCIENCES.

We are dedicated to providing innovative construction solutions for Utah's growing life sciences community.

GENERAL CONTRACTOR

PRECONSTRUCTION SERVICES


DESIGN BUILD

CONSTRUCTION MANAGEMENT



ENGAGECONTRACTING.COM

## VENUE LAYOUT & WI-FI HILTON SALT LAKE CITY CENTER



### **SUMMIT COMPANION APP (WHOVA)**


Whova

Downloading the Whova app allows you to view the agenda, speaker bios, attendee lists, rate sessions, and access deals and information from sponsors and exhibitors. Search "Whova" in the App store/Google Play, download, then register/login with the

same email you used to register for the Summit. Find the event, by searching "Utah Life Sciences Summit." Whova can also be accessed at utahlifesciencessummit.com then click the "Whova" link.

### **ACCESS WHOVA**





# OPENING/PLENARY SESSION



### PLENARY SESSION: BALLROOM



7:15 AM	Buffet Breakfast	
8:00 AM	Welcome Remarks	Kelvyn Cullimore, President & CEO, BioUtah
8:10 AM	Chairman's Report	Mark Paul, Executive Director, University of Utah Center for Medical Innovation
8:20 AM	Life Sciences: A Targeted Industry	Jefferson Moss, Executive Director, Governor's Office of Economic Opportunity
8:30 AM	Al and Structural Impacts in Healthcare	Carter Dredge, BusD, Fellow, Cambridge University / Executive Director, Intermountain Health Institute
9:00 AM	Friend of Industry Award	Taylor Randall, PhD, President, University of Utah
9:05 AM	FDA Town Hall	Michelle Tarver, MD, PhD, Director, Center for Devices & Radiological Health, FDA
9:50 AM	Executive of the Year Award	Fred Lampropoulos, Executive Chairman, Merit Medical
9:55 AM	Fireside Chat: Trade Regulations Affecting Life Sciences	Melissa Holyoak, Commissioner, Federal Trade Commission Jacey Skinner, Of Counsel, Ballard Spahr
10:30 AM	Entrepreneur of the Year Award	Shawn Fojtik, CEO, Distal Access
10:35 AM	The Future of Healthcare in Utah: Navigating Costs, Care and the Coming Silver Tsunami	David Bearss, PhD, CEO, Halia Therapeutics [ Moderator ] Bob Carter, MD, PhD CEO, University of Utah Health Mark Ott, MD, Dean, BYU School of Medicine
11:10 AM	Innovation Impact Award	Nusano
11:15 AM	The Miracle of Modern Medicine	Peter Marks, MD, PhD, Sr. VP of Molecule Discovery & Head of Infectious Disease, Eli Lilly; Former Director, Center for Biological Evaluation and Research, FDA
11:50 AM	Lifetime Achievement Award	Wes Sundquist, PhD, Professor and Chair of Biochemistry, University of Utah
11:55 AM	Fireside Chat: National Security Commission on Emerging Biotechnology	Mayealie Adams, VP of Government Affairs, Danaher Michelle Rozo, Vice Chair, National Security Commission on Emerging Biotechnology
12:30 PM	Networking Lunch	

### AFTERNOON SESSIONS

	<b>BIOUTAH</b> TRACK		
	LOCATION: BALLROOM	HOST: KELVYN CULLIMORE	
1:30 PM	Al in the Life Sciences	David Bearss, PhD, CEO, Halia Therapeutics [ Moderator ] Hariprasad Vankalapati, PhD, CSO and Co-Founder, Biolexis Therapeutics Ian Quigley, PhD, Co-Founder and CEO, Leash Bio Alison O'Mahoney, PhD, VP of Pharmaceutical Research, Seek Labs	
2:10 PM	Understanding GPOs: Are They Right for Your Organization?	Todd Ebert, Retired President & CEO, Healthcare Supply Chain Association	
2:40 PM	The Fundamentals of Reimbursement in U.S. Healthcare	Amanda Morrison, Senior Manager Reimbursement & Market Access, Stryker	
3:10 PM	Break		
3:20 PM	Making Social Media Work for Your Company	Nathan Gwilliam, Founder & CEO, PodUp	
4:00 PM	Mapping Utah's Life Sciences Developments	Chris Kirk, Managing Director, Colliers International [Moderator] Mike Ambre, Executive Director, Point of the Mountain State Land Authority John Dahlstrom, Executive Vice President, General Counsel, Wasatch Group Benjamin Hart, Executive Director, Utah Inland Port Authority J. Steven Price, President & Founder, Price Real Estate	
4:40 PM	Korea's Digital Health Innovation: Smart Hospitals, Medical Al Solutions, and Global Collaboration Pathways	Yeong Yi Yim, Director, Korea Health Industry Development Institute	
4:50 PM	Presentations by Visiting Korean Companies	Jin Kim, CMO, Healcerion Rebekah Walker, Manager, iMediSync Oknam Park, CEO, Medihelpline Geeyoon Kang, CEO, Petraintelligence	

# AFTERNOON SESSIONS



	REGULATORY & QUALITY TRACK		
	LOCATION: ALPINE EAST	HOST: CHRIS PHILLIPS	
1:30 PM	Early Experience with an Evolving FDA & HHS	Seth Olson, Kirton & McConkie [ Moderator ]  Peter Marks, MD, PhD, Sr. VP of Molecule Discovery & Head of Infectious Disease, Eli Lilly Chris Rogers, VP, Regulatory Affairs VAD, BD  Dana Andersen, PhD, Chief Technical & Manufacturing Officer, Denali Therapeutics	
2:10 PM	How Al is Driving Trends in Life Sciences	Ryan Hogan, CEO, Pressure Medical [ Moderator ]  Kelli Oborn, Sr. Technical Specialist & Scheme Manager - Vascular Devices, BSI Group  Heather Murphy, Sr. Clinical Evaluation Specialist - Vascular Access Devices, BSI Group  Brynn Stanley, Associate Attorney, Gardner Law  Josh Gangemi, Manufacturing Engineer, Blackrock Neurotech	
2:50 PM	Break		
3:00 PM	Avenues to Early and Better Regulatory Access	Chris Phillips, VP of Regulatory Affairs and Quality, Epitel [ Moderator ] Kai Kadoich, TAP Advisor, CDRH, FDA Kelli Oborn, Sr. Technical Specialist & Scheme Manager - Vascular Devices, BSI Group Heather Murphy, Sr. Clinical Evaluation Specialist - Vascular Access Devices, BSI Group	
3:35 PM	Clinical Trials Evolving Landscape: A CRO Perspective	Dave Hanaman, CEO, Curavit [ Moderator ]  Amy Goodman, Director, Research & Science, Data Coordinating Center, University of Utah  Chuck Bucklar, Chief Business Officer, Uncommon Cures  Cameron Mealey, Director, Business Development, Avance Clinical	
4:15 PM	Hurry Up! FDA's Quality System Harmonization with ISO 13485	Markus Gee, Director, Life Sciences Division, Axeon	

### AFTERNOON SESSIONS



	<b>WORKFORCE</b> TRACK		
	LOCATION: ALPINE WEST	HOST: ANDY ROBERTSON	
1:30 PM	Utah's Talent Advantage: Up-Skilling & Elevating the Leaders of Tomorrow	Brooke Clark, Principal, Upward Growth Partners [ Moderator ] Rachel Jones, Chief Commercial Officer, VedaBio Lacey Marakis, Fractional Talent Acquisition Leader, Aptarro Charitha Tillekeratne, CTO of Surgical Innovations, GE Healthcare	
2:15 PM	The Utah Talent Hub: A New Tool for Recruiting Interns	Bryce Nelson, Cooperative Education Program Manager, Talent Ready Utah Jimmy McDonough, Asst. Commissioner, Higher Education Workforce Programs, Utah System of Higher Education - Talent Ready Utah	
3:00 PM	Break		
3:15 PM	National and Local Workforce Perspectives: The 2025 TEConomy Report	Ryan Helwig, Principal & Senior Director, TEConomy Partners, LLC	
4:00 PM	Immigration Challenges & Impacts on the Life Sciences Workforce	Kathleen Weron, Partner, Ogletree Deakins Amanda Mullane, Shareholder, Ogletree Deakins	

## AFTERNOON SESSIONS

### ENTREPRENEURIAL & LEGAL TRACK **LOCATION: WASATCH ROOM HOST: SCOTT YOUNG** Scott Young, Partner, Mayer Brown Dr. Rachel Garlick, Founder and CSO, Eris Biotech Building a Life Sciences Company in Utah: Tips 1:30 PM **Greg Larson**, President, Ortho Development from the Trenches Jake Fackrell, Founder and COO of Savvos Health Curtis Anderson, Founder and CEO of Nursa Molecule to Market: The Process of Taking an Idea Neela Pack, Associate, Mayer Brown 2:15 PM from the Operating Room to the Board Room Jeffrey H. Lawson, MD, PhD, Surgeon, Scientist, Innovator 3:00 PM **Break** Natural and Artificial Innovation: Evolving IP Spencer Glende, Partner, Mayer Brown 3:15 PM Matthew Gordon, Vice President - Corporate Legal Affairs, Myriad Genetics Issues in the Life Sciences Sam Gardiner, Partner, Mayer Brown 4:00 PM Financing Best Practices from Seed Round to IPO Liz Walsh, Counsel, Mayer Brown

### **CLOSING RECEPTION**

**LOCATION: EXHIBIT HALL** 

**HOST: KELVYN CULLIMORE** 

5:00 PM

**Reception Opens** 

5:15 PM

Signing of Memorandum of Understanding

Korea Health Industry Development Institute

BioUtah

### M.O.U. SIGNING: KHIDI-BIOUTAH

BioUtah and the Korea Health Industry Development Institute (KHIDI) are entering into a Memorandum of Understanding to expand collaboration between Utah's and Korea's life sciences industries. The partnership will foster cooperation in areas such as international market access, regulatory and reimbursement guidance, business networking, and innovation exchange. Through joint seminars, B2B meetings, and shared insights on global healthcare trends, the two organizations aim to strengthen ties and create new opportunities for companies, researchers, and investors in both regions.









# A REAL-WORLD SURGICAL ENVIRONMENT FOR

### REAL-WORLD IMPACT


Utah's Premier Surgical Training and Innovation Suite, Opening Feb 2026





cmi.uofuhealth.org | CONTACT US





# Accelerate the real-life impact of tommorow's science and technology.

At Danaher, we partner with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life.

Our global teams are pioneering what's next across life sciences, diagnostics, biotechnology and beyond.

See what's next at www.danaher.com



### SUMMIT PARTICIPANTS



MAYEALIE ADAMS VICE PRESIDENT, GOVERNMENT AFFAIRS, DANAHER CORPORATION

With two decades of legal and government affairs experience, Mayealie Adams is responsible for protecting and promoting Danaher's interests at all levels of government. Danaher is a global science and technology innovator with over \$24 billion in annual revenue and 63, 000 employees in 40+ countries around the globe, including over 600 at the Cytiva site in Logan, Utah. Ms. Adams previously held leadership positions with Philips, PNC Bank and FedEx. She serves on a number of non-profit boards including the Washington Heads of Office Leadership Council, Alliance for mRNA Medicines, and the Congressional Award Foundation.



MICHAEL AMBRE
EXECUTIVE DIRECTOR,
THE POINT OF THE MOUNTAIN
STATE LAND AUTHORITY

Michael Ambre is an accomplished and results-driven project leader with a distinguished career marked by expertise in State procurement, contract administration, various construction delivery methods, and exceptional team performance. Since 2023, Ambre has served on the Land Authority board as the division director for the Utah Division of Facilities Construction and Management (DFCM). Ambre worked in various capacities ranging from project manager to division director. During his 24-year tenure at DFCM, he oversaw construction of both the new, state-of-the-art Utah State Correctional Facility and demolition of the decades-old Utah State Prison. For the past two years, Ambre has been actively managing all site preparations at The Point for the construction of critical backbone infrastructure.



DANA ANDERSEN, PH.D. CHIEF TECHNICAL & MANUFACTURING OFFICER, DENALI THERAPEUTICS

Dana Andersen joined Denali Therapeutics in 2018 as the Chief Technical & Manufacturing Officer and is responsible for overseeing the development of manufacturing processes, production, quality control & assurance and clinical supply to support the Denali portfolio. Previously, he worked at Genentech for nearly 23 years and held several leadership roles spanning biologics manufacturing process development. Dana received a Ph.D. from Stanford following a B.S. from the University of Colorado at Boulder, both in chemical engineering with a focus on biological systems, and is a fellow of the American Institute for Medical and Biological Engineering.



CURTIS ANDERSON FOUNDER & CEO, NURSA

Curtis Anderson is the Founder and CEO of Nursa, a nationwide platform that exists to put a nurse at the bedside of every patient in need. From a young age, he used software to improve the world around him. In 2017, he purchased a staffing agency, and quickly saw there was a better way to help nurses, facilities, and patients. Nursa was born in a basement and bootstrapped with personal cash. Nursa has grown to help enable nurses across the country. Curtis is passionate about making the process of care delivery more efficient for everyone. When not at work, you can find him out of cell reception, in the pool or on the ski slopes with his three children and wife Stacie.



DAVID BEARSS, PH.D. CEO, HALIA THERAPEUTICS AND MOLECULERN

David J. Bearss, Ph.D. is an accomplished scientist, entrepreneur, and executive with more than 25 years of experience in drug discovery and development. He currently serves as CEO of Halia Therapeutics, a biotechnology company pioneering therapies that target chronic inflammation and neurodegeneration, and as Chairman of Biolexis Therapeutics, focused on Al-driven drug discovery for metabolic and oncologic diseases. Dr. Bearss has founded or led multiple biotechnology companies and contributed to the development of 18 drugs that have entered clinical trials. His scientific expertise spans cancer biology, inflammation, and molecular pharmacology, and his leadership emphasizes innovation, integrity, and collaboration. Throughout his career, Dr. Bearss has combined deep academic training with entrepreneurial insight to translate cutting-edge science into transformative medicines that improve patients' lives.



CHUCK BUCKLAR
CHIEF BUSINESS OFFICER,
UNCOMMON CURES, INC.

Chuck has over 30 years of commercial and general management experience in the biotechnology/ pharmaceutical industry. During that time, he has held senior positions with increasing responsibilities at companies including Chiron, Cephalon, GPC Biotech, and BioMarin. Chuck's experience at BioMarin included managing the entirety of the US and Canadian commercial operations. His teams successfully launched and commercialized four rare disease products, and managed transformational growth across the entire BioMarin portfolio. His commercial expertise includes product life-cycle stages from early pipeline all the way through loss of exclusivity. Chuck currently serves as the Chief Business Officer at Uncommon Cures, a firm dedicated to pioneering the design and implementation of clinical trials for rare diseases.






BOB CARTER, M.D., PH.D. CEO, UNIVERSITY OF UTAH HEALTH / EXECUTIVE VP, HEALTH SCIENCES, UNIVERSITY OF UTAH

Bob S. Carter, MD, PhD, serves as Executive Vice President for Health Sciences and CEO for University of Utah Health. In his roles leading the health system, Carter works to assure the professional and educational success of more than 27,000 talented faculty, staff, and students who make U of U Health one of the nation's premier academic health centers. Prior to joining the University of Utah in 2025, he served as the William and Elizabeth Sweet Endowed Professor in Neuroscience at Harvard Medical School and Neurosurgeon-In-Chief at Mass General Brigham, Massachusetts General Hospital and Brigham and Women's Hospital. A neurosurgical oncologist and prolific researcher, Carter was elected to the National Academy of Medicine in 2024. Carter received an MD and PhD in epidemiology from Johns Hopkins University and an undergraduate degree in chemistry from Brigham Young University.



BROOKE CLARK FOUNDER AND PRINCIPAL ADVISOR, SEAT 1A ADVISORS

Brooke Clark is the founder of Seat 1A Advisors, guiding leaders to chart bold careers with visibility as a strategic asset. With two decades at the intersection of talent strategy and leadership development, she scaled Recursion Pharmaceuticals from a 40-person startup to a publicly traded biotech, designing systems that fueled rapid growth and elevated emerging leaders. Today, she advises executives across Utah and beyond on workforce strategy and leadership pipelines, positioning exceptional talent to lead the next wave of life sciences innovation.





KELVYN CULLIMORE PRESIDENT & CEO, BIOUTAH

Kelvyn H. Cullimore Jr. was named President and CEO of BioUtah, the state trade association for life science companies in Utah, in October 2018. Mr. Cullimore is a member of the board of the World Trade Center Utah and on the advisory board of the Center for Medical Innovation at the University of Utah. He also serves on the advisory board for the College of Science, Engineering and Technology at Utah Tech University and on the Life Sciences Leadership Council at BYU. From 1992 to 2018 Mr. Cullimore was the President and CEO of Dynatronics Corporation, a leading manufacturer of physical therapy devices and products with an international reach. Dynatronics is a publicly traded company originally founded by Mr. Cullimore and his father in 1979. In addition to his professional career, Mr. Cullimore was elected the first Mayor of Cottonwood Heights, UT in November 2004 and served in that capacity until January 2018. He graduated cum laude from BYU in 1980 with a degree in Financial and Estate Planning.



JOHN DAHLSTROM
EXECUTIVE VICE PRESIDENT,
GENERAL COUNSEL,
WASATCH GROUP

John has led many notable acquisition and development projects for Wasatch. These include several high-rise office building acquisitions in Salt Lake City: Wells Fargo Center, Ken Garff Building, City Centre Building, and Broadway Media Center. New development projects in downtown Salt Lake City include the Questar Center and 222 South Main Street with former partner Hamilton Partners. He has also led the development of several retail projects including Academy Square in North Logan, redevelopment of the Canyon Rim Shopping Center in Holladay, acquisition and redevelopment of The Shoppes at Bountiful Plaza in Bountiful, and The Village Shoppes at Day Dairy in Draper. John has been instrumental in the development of the Medical Innovation Technology Campus in West Valley City, home to Nusano, a physics company committed to bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market.



Thanks to the tireless efforts of BioUtah, the biotech ecosystem in Utah is stronger and the future brighter. We are proud of our partnership with BioUtah. Together, we help our members make the impossible, possible.

BIO. Where Breakthroughs Begin.

Learn more at bio.org



CARTER DREDGE, BUSD CAMBRIDGE FELLOW AND EXECUTIVE DIRECTOR, INTERMOUNTAIN HEALTH INSTITUTE, INTERMOUNTAIN HEALTH

Carter Dredge is a global healthcare thought leader and transformationalist, and currently serves as the executive director of the Intermountain Health Institute, where he partners with some of the world's top thinkers and doers to create novel solutions to complex problems and develop trusted and effective leaders. Prior to his current role as a senior executive at Intermountain Health, Dr. Dredge served at SSM Health as senior vice president and lead futurist and as chief strategy & transformation officer, overseeing strategy, innovation, mergers & acquisitions, research and development, analytics, and business development. Dr. Dredge has been recognized by Modern Healthcare magazine as one of the "Top 25 Innovators" in the United States and was the first American ever accepted into the business doctorate program at the University of Cambridge in the United Kingdom—a program specifically designed for executives who had built or who currently lead major corporations.



JAKE FACKRELL CO-FOUNDER & COO, SAVVOS HEALTH

Jake Fackrell is a seasoned entrepreneur and co-founder of Savvos Health, an Al-powered, digital health, fintech platform transforming how patients, self-funded employer groups, and providers transact in healthcare. A BYU MBA and UVU alum, Jake has launched and scaled multiple multimillion-dollar ventures, including RedX and Domega. An Ironman competitor, mentor, and co-founder of the Change the World Foundation, Jake is passionate about innovation, leadership, and helping people achieve abundance in both business and life.



TODD EBERT, R.PH
PRESIDENT, CEO (RETIRED),
AND GRANDPA

Healthcare Supply Chain Association (HSCA) President and CEO Todd Ebert is a nationally recognized supply chain leader, a group purchasing industry expert, and a registered pharmacist with more than 30 years of healthcare experience. Ebert joined HSCA in 2015 from Amerinet, Inc., a national healthcare solutions organization and HSCA member, where he had served as President and CEO since 2007. After joining Amerinet from Intermountain Healthcare in 1991, Ebert served in a series of leadership roles including Vice President of Amerinet's pharmacy program; President of Amerinet's private-label company, Amerinet Choice, LLC; Executive Vice President for Contracting Operations and Purchasing Program Development Units; President of Operations; and as President and Chief Operating Officer. Prior to Amerinet, Ebert gained extensive experience in several other sectors of the healthcare industry.



### We innovate with purpose

Patients will always inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we will continue to confidently address the most complex healthcare challenges of our time and unlock the potential medicines and technologies of tomorrow.

Learn more at jnj.com

### Johnson&Johnson

© Johnson & Johnson Health Care Systems Inc. 2024 04/24 cp-444096v1



# Fisher Scientific Channel

### Premier Scientific Supplies Partner and Laboratory Product Enabler

The Fisher Scientific channel offers convenient access to the most comprehensive offering of products and services to allow customers in scientific research, safety, healthcare, and education to increase productivity and efficiency.

Visit **fishersci.com** to learn more.





**SHAWN FOJTIK** CFO **DISTAL ACCESS** 

100+ combined issued & pending patents and co-founder of Axiom, CIRCA, Distal Access, Fluidx, Pinyons, PolyEmbo, Transit, VentiV, and other companies with experience at GE, Boston Scientific, and Black & Decker. His intellectual property contributions include cardiovascular angioplasty & delivery catheters; embolic liquids & plugs; blood-clot filters; guidewire controllers; thrombectomy systems; electrophysiology mapping, ablation, & sensing systems; manual & motorized intraosseous access devices; uterine polyp tissue-resectors; and other technologies with 1+ million safe-patient uses. Shawn is a retired Adjunct Assistant Professor at the University of Utah with a BS from the University of Illinois and a MA from Harvard University.



JOSH GANGEMI MANUFACTURING ENGINEER, **BLACKROCK NEUROTECH** 

Joshua Gangemi is the Manufacturing/Design Transfer Engineer at Blackrock Neurotech, helping bring leading edge neurotechnology from concept to production. Josh built his foundation in the Boston biotech scene, working with Medtech and Pharma companies such as Haemonetics, Seres Therapeutics, and Lyndra Therapeutics on process engineering, validation, and product development. Josh focuses on continuous improvement and collaboration to drive meaningful advances in human health. Outside of medical devices Josh is a runner & fitness enthusiast trying to stay athletic between ACL surgeries and ankle sprains.



Utah-MEP is dedicated solely to the success of Utah companies, providing outreach, value-added training, education, workforce development, certifications, and needs-driven services to Utah manufacturers and rural businesses.



### **DEMAND**

- **Grow Sales**
- Marketing/SEO
- Global Markets Made in Utah
- **Awards**



### **LEADERSHIP**

- **Executive Camps**
- Strategic Planning
- Management
- Financial Analysis
- Culture Training



### CAPACITY

- 55 Organization
- Lean-SS Events
- Supply Chain
- Hire and Retain Lead Training



### **COMPLIANCE**

- ISO/AS Quality
- International
- Food Safety
- Safety/Hygiene





### **TECHNOLOGY**

- **Product Development**
- Cybersecurity
- **Advanced Materials** Automation and Al
- Industry 4.0





info@utah-MEP.org (801) 587-0713



SAM GARDINER PARTNER, MAYER BROWN

Sam Gardiner is a partner in the Salt Lake City office of Mayer Brown and a member of the Emerging Companies & Venture Capital, Mergers & Acquisitions, and Capital Markets practices. Sam is also part of the Life Sciences and Technology industry groups. For over 24 years, Sam has been a trusted advisor to his clients in a full range of transactional matters. His M&A experience includes counseling buyers or sellers in financial or strategic transactions involving private or public companies in a wide variety of industries. Sam also advises companies and investors in early-stage, venture capital and other private equity financings, debt financings, registered public equity financings, PIPEs, recapitalizations, restructurings and strategic partnering transactions. In just the last decade, Sam has assisted clients in more than 100 mergers and acquisitions, financings, or similar transactions.




RACHEL GARLICK, PH.D. FOUNDER AND CSO, ERIS BIOTECH

Dr. Rachel Garlick is the co-founder of Eris Biotech, a Utahbased startup backed by Y Combinator that is working to develop safer, smarter cancer immunotherapies. Rachel received her PhD from Dartmouth College in Immunology and is now creating new treatments for patients who don't respond to current cancer care.





Image: Accelerated particles flow toward a square target inside Nusano's production facility. When the particles collide with the target material, radioisotopes are created. [Artist's rendering]



### FORGING NU-FRONTIERS

### Breakthrough physics enabling innovations in healthcare and beyond

Nusano is working to stabilize supply chains, advance American national security by reducing dependency on foreign supply, and enable once-in-a-generation innovations in fields ranging from healthcare to nuclear energy.

Headquartered in West Valley City, Utah, Nusano is commercializing platform technologies for radioisotope production, stable isotope enrichment, and advanced separation techniques.

Together, these proprietary systems and methods are poised to supply the fight against cancer, fuel the nuclear renaissance, and deliver critical minerals for the modern world.



### **MEDICAL RADIOISOTOPES**

Producing critical ingredients needed for new cancer therapeutics



### **CRITICAL MINERALS**

Applying proprietary separation and purification technologies to jumpstart domestic minerals production



#### HALEU

Generating fuel for nextgeneration small modular reactors



### **NUCLEAR BATTERIES**

Using radioisotopes to provide always-on power in the harshest environments

### REVOLUTIONIZING MEDICAL RADIOISOTOPE PRODUCTION



The promise of medical radioisotopes has for too long been held back by technical limitations, supply outages, and waste stream concerns. The Nusano production platform is poised to address all these issues – making a wide variety of isotopes available to drugmakers, researchers, and clinicians.

Learn more about our technologies at nusano.com.




MARKUS GEE
DIRECTOR, LIFE SCIENCES
DIVISION,
AXEON

Markus adds his 30 years of in-depth medical device product realization, quality systems development and deployment, worldwide regulatory expertise skills and experiences to the Axeon team. Markus assists many growing companies attain and retain their QMS certification and compliance goals. This includes 21 CFR 820, ISO 13485:2016, ISO 9001:2015, MDSAP country specific requirements, and MDR 2017/745 compliance & CE Marking certifications.



SPENCER GLENDE, J.D. PARTNER, MAYER BROWN LLP

Spencer Glende is a partner in Mayer Brown's Technology & IP Transactions practice. He advises dynamic companies and investors on matters related to developing, acquiring, and commercializing technologies and intellectual property. Spencer has structured and negotiated numerous lifesciences transactions, such as R&D collaborations, clinical trial agreements, and technology licenses, and he routinely handles IP aspects of acquisitions and other corporate deals. Spencer graduated from the University of Utah and UC Berkeley Law, and spent several years with a leading Silicon Valley law firm before bringing his practice home to Salt Lake City.





AMY GOODMAN, PH.D.
DIRECTOR, RESEARCH &
SCIENCE, UNIVERSITY OF UTAH
DATA COORDINATING CENTER

Dr. Amy M. Goodman is a clinical scientist and biomedical engineer with expertise in designing and implementing multi-center interventional clinical studies both in industry and within academic institutions. She received her PhD in biomedical engineering from Duke University and has held various engineering, clinical, and leadership positions in early stage medical device companies focused primarily on neuromodulation and electrophysiology. At the Utah Data Coordinating Center, Dr. Goodman is responsible for Industry Partnerships, Business Development, Regulatory Affairs, and Quality Assurance. She is an inventor on 11 issued patents and an author on numerous abstracts and manuscripts.



MATTHEW GORDON
VP, CORPORATE LEGAL AFFAIRS,
MYRIAD GENETICS

Mat Gordon is a seasoned legal executive with a passion for helping clients achieve their goals through cross-functional partnership, keen legal acumen and strong business sense. With over 16 years of experience in the life science and biotechnology industries, Mat brings expertise in complex deal negotiations, dispute and litigation management, overseeing and leveraging intellectual property, healthcare compliance and regulatory affairs. Mat serves on Myriad's Artificial Intelligence Governance Committee.



Berkshire Hathaway HomeServices Utah Properties has 60+ experienced, knowledgeable relocation certified agents. We have the resources to ensure that your employees are treated with concierge services from arrival to departure and provided comprehensive knowledge while on a house hunting trip. Services include **Group Moves**, **Area Tours**, **Home Sale Assistance/Departure Services**, and **Destination Services (DSP)**.

We're here to help guide the entire process and look forward to working with you.

Please contact us at Relocation@BHHSUtah.com or call (801) 990-1481 to speak to one of our Relocation Specialists.
BHHSUtah.com/Relocation



©2025 BHH Affiliates, LLC. An independently owned and operated franchisee of BHH Affiliates, LLC. Equal Housing Opportunity.



NATHAN GWILLIAM CEO, PODUP

Nathan Gwilliam is a serial entrepreneur who has created and sold 3 ventures, including Adoption.com, the world's most-visited adoption platform. He is currently the Founder and CEO of PodUp, a podcasting platform with 60+ tools to create, grow, and monetize a venture with a podcast. PodUp also provides done-for-you podcast creation, guest booking, publishing, syndication, marketing, and monetization. He sold a business to Deseret Digital Media (KSL, Deseret News, etc.), and built/grew platforms for them that reached 280 million monthly uniques, with 130 million social follows and 40 million+ monthly comments, likes, and shares. He was awarded "Best of the Decade" by the BYU Center for Entrepreneurship & Technology.



BEN HART
EXECUTIVE DIRECTOR,
UTAH INLAND PORT AUTHORITY

Benjamin Hart serves as the executive director of the Utah Inland Port Authority (UIPA). During his tenure at UIPA Hart has prioritized economic optimization with port facility development, along with strong internal controls and transparency for the organization. Under his leadership the Port is focused on statewide, along with regional projects and ensuring world-class global access for Utah businesses. Prior to his position at UIPA, Hart served as the deputy director of the Utah Governor's Office of Economic Opportunity. He completed both his undergraduate and graduate studies at the University of Utah, where he currently serves as an adjunct instructor.



**DAVE HANAMAN**PRESIDENT & CO-FOUNDER,
CURAVIT

Dave Hanaman is President and Co-Founder of Curavit, the Innovation CRO. Dave leads its sales, marketing, product development, and alliance strategies. Dave represents Curavit within industry organizations and at conferences dedicated to positively-disrupting clinical research to accelerate health, longevity, and treatments for patients. He is a proven entrepreneur, operator, and board director with successful, strategic exits to public companies. Dave graduated from the University of California at Berkeley and served as a deployed U.S. Navy officer.



Our Medicine Assistance Tool is an easy-to-use site that may help you and your family save when buying medicines.





RYAN HELWIG PRINCIPAL & SENIOR DIRECTOR, TECONOMY PARTNERS

Ryan joined TEConomy Partners from his previous position as a senior economist with the Technology Partnership Practice at Battelle. Mr. Helwig is an accomplished economist and consulting professional with nearly 30 years of experience spanning the public, private, and non-profit sectors. His experience encompasses an early career spent with the U.S. Department of Labor's Bureau of Labor Statistics and the Economic Policy Institute in Washington, D.C., followed by senior project management experience within Battelle prior to co-founding TEConomy Partners in 2015. Since 2006, Ryan has been a primary author of biennial reports for the Biotechnology Industry Organization (BIO) that assess the "state-of-the-states" in bioscience sector development. His diverse knowledge base and research skills have led to conducting numerous signature projects in regional cluster strategy, economic impact analysis, competitive benchmarking assessments, and workforce



RYAN HOGAN CEO, PRESSURE MEDICAL

Ryan Hogan brings over two decades of legal and compliance expertise across enterprise and start-up environments. His leadership encompasses comprehensive regulatory programs including GDPR, FDA, FTC, CoTCCC, and HIPAA compliance. Working collaboratively with C-suite executives and boards, Ryan has successfully negotiated high-value contracts, navigated complex audits, and built high-performing compliance teams globally. Through speaking engagements, Ryan demystifies regulatory complexities, transforming legal language into practical insights. His presentations cover global data privacy, risk mitigation frameworks, and corporate governance, empowering professionals to anticipate challenges and capitalize on opportunities. Ryan's strategic approach transforms compliance from liability into competitive advantage, aligning regulatory mandates with business objectives to drive organizational success.



# Our Life Sciences Expertise

### MAYER | BROWN

Eleven Mayer Brown partners named "Life Sciences Stars," two counsel named "Rising Stars" and four practice areas ranked in the 2025 edition of Euromoney's Legal Media Group (LMG) Life Sciences.

Our advice reflects a broader view of the business environment, informed by our life sciences experience. With a multidisciplinary team of lawyers, many dual-qualified with doctorate and master degrees in biochemistry, biology, medicine, and pharmacy, we have an acute understanding of life sciences companies.

Substantial experience, gained by working across business areas within this sector and other industry-leading organizations provides us with indispensable insights to handle legal and regulatory challenges.


We are skilled in dealing with matters related to life sciences industries globally, including capital markets, risk management, intellectual property, dispute resolution, antitrust and competition, investigations and compliance, government and global trade, tax and transfer pricing, and regulatory and environmental matters.

Our geographic reach in the world's key business and finance centers allows us to assist clients in structuring and coordinating cross-border transactions.

# Great ideas need smart capital (and smarter counsel).

"Mayer Brown's clients include start-ups, major pharmaceutical, biotech and medical device companies, financial institutions, funds and other investors."

-The Legal 500 US





MELISSA HOLYOAK COMMISSIONER, U.S. FEDERAL TRADE COMMISSION

Melissa Holyoak has been a Commissioner of the Federal Trade Commission since March 2024. She has been a strong advocate for the FTC's law enforcement work to promote competition and protect consumers from fraud and other unlawful practices. Commissioner Holyoak has extensive experience as a litigator and leader. Immediately prior to joining the FTC, she served as Solicitor General with the Utah Attorney General's Office, where she oversaw the civil appeals, criminal appeals, constitutional defense and special litigation, and antitrust and data privacy divisions. She also managed multi-state matters including those involving consumer protection and antitrust claims. Before taking on that role, she served as president and general counsel of Hamilton Lincoln Law Institute, a Washington, DC-based public interest law firm, and in other public interest attorney positions with the Competitive Enterprise Institute and the Center for Class Action Fairness.



RACHEL JONES
CHIEF PRODUCT OFFICER,
VEDABIO

Rachel Jones has over 25 years of experience in molecular diagnostics and a proven record of building and scaling commercial organizations to deliver groundbreaking clinical solutions. As Chief Commercial Officer at BioFire Diagnostics (now bioMérieux), she launched and expanded novel infectious disease platforms, establishing the company as the market leader in syndromic testing and guiding it to \$1 billion in revenue. Rachel's expertise spans marketing, market access, reimbursement, and program management, with a consistent focus on driving adoption of transformative technologies. She is recognized for turning innovation into impact through strategic commercialization and business growth.





KAI KADOICH TAP ADVISOR, FDA / CDRH / TAP PROGRAM

Kai's 16-year medtech career has spanned a variety of consulting, industry, and now government roles. At L.E.K. Consulting, Kai advised medtech and pharma companies on market entry, competitive strategy, and portfolio decision making. At Medtronic, Kai worked in the Japan region and the Cardiovascular and Neuromodulation businesses, where he held leadership roles in marketing, strategy, business development, and business management. Kai has experience with all stages of the medtech product lifecycle including M&A/investing, portfolio planning, product development, product launch, commercialization, and market development. Kai joined the FDA as a TAP Advisor in 2023 and is based in Minneapolis, MN, where he supports the local medtech ecosystem.



CHRIS KIRK
MANAGING DIRECTOR,
COLLIERS

Chris Kirk serves as Managing Director of Colliers International's Salt Lake City Downtown office, leading brokerage and advisory services across Utah's office and life science sectors. With nearly 30 years of experience, Chris is known for his market expertise, strategic insight, and ability to bring together key industry leaders. He holds the prestigious SIOR designation, has served as president of SIOR Utah, and sits on the board of the Utah Downtown Alliance. A passionate advocate for Utah's growth and innovation, Chris pairs his enthusiasm for the region with a lifelong love of the outdoors.



# THANK YOU BIOUTAH

For Elevating Life Sciences Globally





FRED LAMPROPOULOS EXECUTIVE CHAIR, MERIT MEDICAL

Career Highlights: Chair of the Board, CEO and President of the Company from its formation in 1987 to October 2025; Chair of the Board and President of Utah Medical Products, Inc. (medical device manufacturer), 1983 to 1987; Filed more than 500 domestic and international patents and applications on medical devices; Serves on several community and advisory boards; Recipient of numerous community and industry awards, including 2003 and 2018 Utah Governor's Medal for Science and Technology, and the BioUtah Lifetime Achievement Award. The Board believes the Company benefits immensely from Mr. Lampropoulos' experience as founder, President and Chief Executive Officer. He plays an essential role in communicating the expectations, advice, concerns and encouragement of the Board to our employees. Mr. Lampropoulos has a deep knowledge and understanding of the Company, as well as the industry and markets in which our products compete.



GREG LARSON
PRESIDENT,
ORTHO DEVELOPMENT
CORPORATION

Greg Larson is the President and a member of the Board of Directors of Ortho Development Corporation, a Utah-based medical device company improving patient mobility through innovative hip and knee replacement solutions. With 25 years in orthopedics, Greg has championed strategic growth, operational excellence, and product development expansion. Prior roles include CFO and Controller at Ortho Development, and he began his career in audit at Deloitte. Greg holds a Master of Accountancy degree from Brigham Young University and is committed to advancing Utah's life sciences ecosystem and better outcomes for patients.





JEFFREY LAWSON, M.D., PH.D. SURGEON, SCIENTIST, INNOVATOR, DUKE UNIVERSITY

Dr. Lawson received his Medical Degree and a Ph.D. in Cell and Molecular Biology from the University of Vermont where he also completed a Postdoctoral Fellowship in Biochemistry. Dr. Lawson continued his clinical training with a residency in General and Thoracic Surgery and a Fellowship in Vascular Surgery at Duke University where he joined the faculty as both a surgeon and scientist. He was formerly Professor and Vice Chair of Research in the Department of Surgery at Duke with a robust clinical practice and basic science laboratory. He also served as the Director of the Vascular Surgery Research Laboratory, oversaw clinical trials for the Department of Surgery, and led the General Surgery Research Residency Program.



LACEY MARAKIS FRACTIONAL TALENT ACQUISITION LEADER, APTARRO

Lacey Marakis is a strategic and data driven Global Talent Acquisition leader with 20 years of experience scaling teams across the techbio, life sciences, and health tech industries. As the Fractional Talent Acquisition leader at Aptarro, she partners with executives to design modern, inclusive, and data informed hiring strategies that enable sustainable growth. Previously, she led global recruiting and DEI initiatives at Recursion and Edwards Lifesciences, driving international expansion and operational excellence. Lacey is recognized for building equitable, scalable talent systems that balance strategy, innovation, and culture.



CHRIS LOWE CEO, NUSANO

Chris Lowe is the Chief Executive Officer of Nusano, a privately held physics company working to stabilize supply chains, advance American national security by reducing dependency on foreign supply, and enable once-in-ageneration innovations in fields ranging from healthcare to nuclear energy. The company is commercializing platform technologies for radioisotope production, stable isotope enrichment, and advanced separation techniques. Together, these proprietary systems and methods are poised to supply the fight against cancer, fuel the nuclear renaissance, and deliver critical minerals for the modern world. Mr. Lowe majored in Business at California Polytechnic State University and holds an MBA in Finance from St. Mary's University.



EXPERIENCE. LEADERSHIP.
RESULTS.

Providing Legislative, Regulatory and Policy Solutions to Clients in The Life Sciences Community

Jeffrey J. Kimbell, President Jeffrey J. Kimbell & Associates, Inc. Park City, UT & Washington, DC

www.kimbell-associates.com jkimbell@kimbell-associates.com 202-735-2590



Cardiovascular • Electrophysiology • Electrosurgical • Imaging

Improving Lives Through Medical Device Innovation



PETER MARKS, M.D., PH.D. SENIOR VP MOLECULE DISCOVERY & HEAD OF INFECTIOUS DISEASE, ELI LILLY

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women's Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. In 2012, he joined the Food and Drug Administration and served as Director of the Center for Biologics Evaluation and Research from 2016 to 2025. He is currently Senior Vice President for Molecule Development and Head of Infectious Disease at Eli Lilly and Company, has published extensively, and is a member of the National Academy of Medicine.



JIMMY MCDONOUGH
ASSISTANT COMMISSIONER,
HIGHER EDUCATION
WORKFORCE PROGRAMS,
UTAH SYSTEM OF HIGHER
EDUCATION-TRU

Jimmy T. McDonough is the Assistant Commissioner for Higher Education Workforce Programs at the Utah System of Higher Education (USHE) - Talent Ready Utah, where he works at the intersection of education, workforce development, and industry collaboration. With over two decades of workforce experience, Jimmy plays a pivotal role in ensuring Utah's colleges and universities remain responsive to evolving industry needs through the creation of industry-aligned degree programs and the infusion of work-based learning across higher education. Throughout his career, Jimmy has advanced strategies that expand career pathways while also shaping new academic programs designed in direct response to employer demand. His leadership has guided the development of internships, apprenticeships, and cooperative education models that not only provide students with real-world experiences but also embed those experiences into academic pathways.

### J.P.Morgan

# Advancing breakthroughs, together

We are committed to fostering connections that drive investment and innovation in the life sciences industry.

© 2025 JPMorgan Chase & Co. All rights reserved.



CAMERON MEALEY DIRECTOR, BUSINESS DEVELOPMENT, AVANCE CLINICAL

Cameron Mealey is Senior Director of Business Development at Avance Clinical, where he partners with emerging biotech companies to move programs quickly from first-in-human studies through later phases. He helps sponsors tap into Australia's speed and incentives for Phase I, while ensuring a smooth path into Phase II/III trials in the U.S. With prior leadership roles at Linical and IQVIA, Cameron has supported programs across oncology, rare disease, neurology, and specialty therapeutics. Based in Salt Lake City, he's passionate about building partnerships that drive innovation and bring new treatments to patients faster.



# Doing work today, for all your tomorrows

Wherever care happens, BD will be there. Just as it has done for more than 125 years, BD remains committed to innovating and delivering impactful solutions and services for healthcare professionals whenever they need it, and wherever care is delivered.

Visit **bd.com** to learn more.





AMANDA MORRISON SENIOR MANAGER REIMBURSEMENT & MARKET ACCESS, STRYKER

Amanda Morrison has over 20 years of experience in health economics, market access, and medical device reimbursement. She is the Senior Manager of Reimbursement and Market Access for Stryker Interventional Spine, where she leads a national team of reimbursement professionals dedicated to supporting patient access. Amanda collaborates across clinical, regulatory, sales, and marketing functions to ensure new technologies are properly coded, reimbursed, and accessible. Amanda has successfully guided payer strategy, secured favorable coding and payment pathways, and supported clinical evidence generation to demonstrate value. She holds CPC and CASCC certifications, an MBA from the University of Montana, and a BS in Cell Biology and Neuroscience from Montana State University.



JEFFERSON MOSS
EXECUTIVE DIRECTOR,
GOVERNOR'S OFFICE OF
ECONOMIC OPPORTUNITY
AND NUCLEUS INSTITUTE

Jefferson Moss serves as the Executive Director of the Nucleus Institute and the Governor's Office of Economic Opportunity (GOEO). He brings extensive experience in entrepreneurship, venture capital, investments, and legislative service, and has played a key role in driving innovation and economic development in Utah. His diverse background includes founding several businesses and holding private banking roles at Credit Suisse and KeyBank. He has served as Chair of the UVU Endowment Investment Committee and is the founder of both the UVU Wolverine Fund and the Utah Innovation Fund. Moss has also held leadership positions as Associate Commissioner of Innovation for the Utah System of Higher Education, Board Member of the Utah State Board of Education, City Council Member and Planning Commissioner of the City of Saratoga Springs, Executive Director of the Innovation District at The Point, and Majority Leader in the Utah House of Representatives.





AMANDA MULLANE SHAREHOLDER, OGLETREE, DEAKINS, NASH, SMOAK & STEWART, P.C.

Ms. Mullane's legal practice is focused on employmentbased immigration law. She is legal counsel to corporate clients within the high-tech industry, predominately the telecommunications, biotechnology and information technology sectors, as well as in the pharmaceutical, financial services, and healthcare industries. In addition to corporate client management, she also represents individual clients on family-based immigration matters and naturalization. Ms. Mullane advises corporate clients and their foreign national employees on all aspects of employment-based immigration. Further, Ms. Mullane routinely advises corporate clients on various compliance matters. This includes the impact of and compliance steps needed in response to corporate mergers, acquisitions and reductions in force, as well as areas of immigration enforcement such as I-9 audits, E-Verify compliance, ICE and USCIS site visits and Public Access File compliance.



AARON MURDOCK CORPORATE PARTNER, MAYER BROWN LLP

Aaron Murdock is the managing partner of Mayer Brown's Salt Lake City office and a member of the firm's Emerging Companies & Venture Capital practice. Aaron provides strategic counsel to technology and other high-growth companies, venture capital funds and private equity funds.



HEATHER MURPHY
SENIOR CLINICAL EVALUATION
SPECIALIST REGULATORY
SERVICES, BRITISH STANDARDS
INSTITUTION

Heather Murphy, RN, BSN, MSHS is a Senior Clinical Evaluation Specialist at the British Standards Institution, where she has worked since February 2021. She has over 10 years of clinical experience in pediatric and adult intensive care and leading vascular access teams. Heather also has a strong medical device industry background, having served as a Quality Manager with global responsibility for QA/QC systems and as an MDSAP SME, ensuring compliance with FDA, ISO 13485, and global regulations. She is known for her technical expertise, collaborative leadership, and commitment to patient safety and regulatory excellence.




BRYCE NELSON
COOPERATIVE EDUCATION
PROGRAM MANAGER,
TALENT READY UTAH

Bryce is facilitating Utah's first state-wide co-op, working with the TRU team towards the mission of building a highly-skilled workforce while providing students with increased career and education opportunities. She enjoys the challenges presented by establishing research-informed programming aligned with the needs of students, industry, and academic stakeholders.



ALISON O'MAHONY, PH.D VP, PHARMACEUTICAL RESEARCH, SEEK LABS

Dr. Alison O'Mahony is Vice President of Pharmaceutical R&D at Seek Labs, leading multidisciplinary teams integrating AI/ML, bioengineering, lab operations, and data analytics to accelerate next-generation therapeutics for infectious diseases and oncology. With over 25 years of experience across phenotypic drug discovery, translational biology, and bioinformatics, Alison has served in leadership roles at Recursion Pharmaceuticals, Eurofins, and DiscoverX. A trained research immunologist and former Staff Investigator at the Gladstone Institutes (UCSF), she is passionate about data-driven, Al-powered, human-centric innovation to support global health. Alison serves as President of the Inflammation Research Association, and sits on advisory boards for TRU, BCR and others. She is a passionate advocate for women in STEM and a member of BioHive's WITS chapter.







**KELLI OBORN**SENIOR TECHNICAL SPECIALIST,
BSI GROUP

Kelli Oborn is a medical device engineer with over 12 years of experience, specializing in the design, testing, and manufacturing of central catheter devices. Throughout her career, Kelli has led the development of multiple catheter systems, focusing on optimizing performance, safety, and manufacturability to meet patient needs. Her hands-on expertise spans the full product lifecycle, from initial design concepts to final product launch. For the past seven years, Kelli has been a Senior Technical Specialist at BSI, where she leverages her deep industry knowledge to evaluate the technical and clinical data for various vascular devices. In her role, Kelli reviews data to ensure these devices are safe, perform as intended, and comply with regulatory standards. Her combination of engineering experience and regulatory insight provides a unique perspective on the complexities of vascular device design and performance.



MARK OTT, M.D.
INAUGURAL DEAN,
BYU SCHOOL OF MEDICINE

Dr. Ott was named Dean of the new BYU School of Medicine on October 10, 2024, as he was finishing his career as an educator, leader and surgical oncologist with Intermountain Health. Dean Ott has held academic and affiliate appointments at Johns Hopkins, Harvard Medical School, Stanford School of Medicine and the University of Utah School of Medicine. He is the recipient of numerous awards and honors, including the department of surgery's faculty teacher of the year award at the University of Utah and the Intermountain Health Lifetime Achievement Award for extraordinary service to medicine. Dean Ott holds a bachelor's degree and a Doctor of Medicine degree from the University of Utah. He served his medical internship and residency in general surgery at Johns Hopkins, where he was also a research and clinical fellow specializing in surgical oncology.



SETH OLSON ATTORNEY, KIRTON MCCONKIE

Seth Olson is an FDA regulatory attorney at Kirton McConkie in Salt Lake City. He advises domestic and international clients on regulatory, compliance, and transactional matters involving the U.S. Food and Drug Administration (FDA) and other federal health agencies, including companies in the medical device, pharmaceutical, biotechnology, human cell and tissue product, food, dietary supplement, and cosmetic industries. Seth leverages his experience as a former Regulatory Counsel at FDA and his extensive experience advising large and small companies faced with complex regulatory, compliance, and enforcement challenges to provide his clients with strategic and pragmatic solutions.





NEELA PACK SENIOR ASSOCIATE, MAYER BROWN

Neela Pack is a senior associate in the Salt Lake City office of Mayer Brown and is a member of the Emerging Companies & Venture Capital, Mergers & Acquisitions, and Corporate & Securities practices. Neela provides strategic advice to companies, private funds, investors, and boards of directors. Her client base reflects the vibrant and dynamic Silicon Slopes ecosystem, innovating across a number of industries, including fintech, technology/SaaS, consumer retail, healthcare, and food and beverage.



MARK PAUL
EXECUTIVE DIRECTOR,
CENTER FOR MEDICAL
INNOVATION, UNIVERSITY
OF UTAH HEALTH

After spending 15 years of Global President of Stryker Neurovascular and 21 years at Boston Scientific, Mark Paul retired from industry and took the leadership role of the Center for Medical Innovation at University of Utah Health. While leading Stryker Neurovascular, Mark grew revenues from \$230M to over \$1.3B and expanded the business to +65 countries. At BSC, Mark held a variety of leadership roles including Director of Peripheral Vascular in Europe, VP GM of International and President of BSC Neurovascular. Mark serves on a variety of state and industry boards, including Chair of BioUtah and Utah Innovation Fund.

## Harnessing Genetic Resilience to Restore Health

Utah Life Science Summit 2025

Halia Therapeutics is pioneering resilience-based therapies that modulate NEK7/NLRP3 to restore balance across inflammatory and neurodegenerative diseases.

#### **Key Achievements**

- HT-6184 (Ofirnoflast): Phase 2 completed in MDS; advancing to Phase 2 obesity combo with Semaglutide showing enhanced efficacy and tolerability.
- HT-4253: LRRK2/RAB10-pathway inhibitor moving into Phase 2 for Alzheimer's disease following a successful Phase 1 safety study.
- GENMOR-AI Platform: Identifies protective genetic modifiers to discover novel drug targets based on human resilience.



Contact Us





CHRIS PHILLIPS
VP, REGULATORY AFFAIRS
& QUALITY,
EPITEL

Chris Phillips is an experienced leader in medical device regulatory affairs, clinical affairs and quality assurance. Chris has helped bring innovative medical devices to market in the USA, Europe, Canada, Australia, Brazil, and other global markets. He has also built and maintained ISO 13485- and 21 CFR 820-compliant quality management systems. Chris has played key roles in designing, developing, and launching novel software-based medical devices, digital health software, implantable medical devices and disposable medical devices. Chris completed a Master of Science degree in Health Sciences from George Washington University focused on regulatory affairs.



J. STEVEN PRICE
PRESIDENT & FOUNDER,
PRICE REAL ESTATE

J. Steven Price is founder and president of Price Real Estate. He owns, develops, and manages over 5 million square feet of industrial, distribution, manufacturing, and urban core adaptive reuse buildings. The portfolio consists of 120+ local, regional, national, and international tenants in economic clusters in bio and life science, aerospace and defense, automotive, food grade facilities, transportation, supply chain, logistics, fulfillment, e-commerce, and outdoor recreation sectors. Within the community, Steven is honored to serve on the Organizing Committee for the 2034 Olympic and Paralympic Winter Games, as well as chair of the Arts & Culture Committee for the 2034 Winter Games.



IAN QUIGLEY, PH.D. CEO & CO-FOUNDER, LEASH BIOSCIENCES

lan Quigley started Leash Biosciences, a computational chemistry company that collects massive amounts of physical measurements in an automated lab, in the basement of his house with Andrew Blevins. Prior to Leash, he was at Recursion, and the Salk Institute before that.








TAYLOR RANDALL, PH.D. PRESIDENT, UNIVERSITY OF UTAH

Taylor R. Randall was selected by the Utah Board of Higher Education as the 17th president of the University of Utah in August 2021. An award-winning educator, innovative leader, and champion of higher education, he comes to the position with more than two decades of experience at the U, serving as both dean of and an accounting professor in the David Eccles School of Business. He is the first alumnus since 1973 to serve as president. Randall began his tenure by declaring a bold vision to make the U a top 10 public university with unsurpassed societal impact. His strategy outlines three objectives: to inspire a new generation of students by revolutionizing the student experience, innovate and generate discoveries that change the world, and serve our state to impact the lives of all 3.5 million Utahns. The vision includes goals to increase enrollment to 40,000 students and secure \$1 billion in research funding annually.





ANDY ROBERTSON
INTERIM EXECUTIVE DIRECTOR,
BIOHIVE

Andy Robertson is the Interim Executive Director of BioHive, Utah's public-private partnership building, branding, and bringing together the state's life sciences ecosystem.

A classically trained and award-winning life science marketer, he's known as a cross-functional "Chief of Getting Stuff Done." Andy has made his mark from Fortune 200 companies to startups, launching over 15 medical devices that generated \$38M in first-year sales. His expertise spans strategy, operations, M&A integration, investor and public relations, fundraising, product management and new product development. A dedicated family man, he also spends an inordinate amount of time honing his mediocre cycling prowess.



CHRISTOPHER ROGERS VP, REGULATORY AFFAIRS, BECTON DICKINSON

Christopher Rogers is the vice president of regulatory affairs for Becton Dickinson's Advanced Access Devices (AAD) and Peripheral Intravenous Catheter (PIVC) business platforms. He is an accomplished business leader with over 20 years of diverse experience in the medical technology industry and an extensive record of successfully bringing new products to global markets. Prior to BD, he held leadership roles in product development, research and testing, and regulatory affairs with J&J, Baxter, and Stryker. He is passionate about driving innovation and applies his broad, cross-functional skill set to identify, develop, and launch new technologies to benefit patients worldwide.



Access the real price of healthcare

Tired of the same 8–10% renewals every year? **So were we.** 



Nomi Health delivers a new operating system for self-funded healthcare—connecting payments, analytics, and direct access so you can finally see the real price of healthcare and act on it.

#### Our solutions



#### **Analytics**

An industry-leading benefits analytics platform that delivers real-time insights to uncover cost drivers, optimize performance, and design smarter, data-backed benefit strategies.



#### **Direct Network**

Direct provider contracts at market-leading rates—members pay \$0 out of pocket while employers gain real savings and simplified access to high-quality care.



#### Rx Management

A transparent pharmacy benefit manager that reduces drug costs and provides employers with visibility into pharmacy spend-without restricting member access.



#### **Financial Services**

A modern payment infrastructure built for healthcare. Brings the flexibility and sophistication of fintech to provider payments—giving you full visibility and control.

#### Nomi by the numbers:

\$200B+

Managed healthcare spend

4.5K+

Employer groups

30M

Lives on platform





MICHELLE ROZO, PH.D.
VICE CHAIR, NATIONAL SECURITY
COMMISSION ON EMERGING
BIOTECHNOLOGY

Dr. Michelle Rozo is currently serving as Vice Chair of the National Security Commission on Emerging Biotechnology, a U.S. legislative branch advisory entity charged with conducting a thorough review of how advancements in emerging biotechnology and related technologies will shape current and future activities of the Department of Defense. Dr. Rozo is also Vice President of Technical Capabilities at In-Q-Tel, a non-profit strategic investor that accelerates the development and delivery of cutting-edge technologies to enhance the national security of the United States. From 2021 to 2022 she was Director of Technology and National Security at the U.S. National Security Council, where she advised the President and National Security Advisor on biotechnology and national security policy, and was also previously the Principal Director for Biotechnology within the Office of the Under Secretary of Defense for Research &



BRYNN STANLEY ASSOCIATE ATTORNEY, GARDNER LAW

Brynn advises FDA-regulated clients on quality, regulatory, and compliance matters. She counsels clients – from small startups to global international companies – on a wide range of issues, from clinical trials to product development and regulatory submissions, quality management system (QMS) audits and implementation, and supplier and supply chain management and control. With Brynn's wide-ranging in-house experience as an engineer along with her private practice experience as an attorney, she understands both the technical and legal challenges that her clients face. That knowledge and experience allows her to provide solutions that are not only compliant with the law, but also practical and actionable.



Engineering at the Department of Defense.

JACEY SKINNER OF COUNSEL, BALLARD SPAHR LLP

Jacey Skinner is an attorney at Ballard Spahr LLP and is former General Counsel to Governor Gary Herbert. As General Counsel, she advised the Governor, his staff and acted as the Governor's legislative director. Her current practice focuses on public policy, administrative law, board governance and litigation. Jacey serves on a number of boards including the Utah State University Board of Trustees, First Lady Abby Cox's Show Up Board, and the Ballet West Board of Directors. She received her bachelor's degree from Utah State University and her J.D. from Brigham Young University. Jacey Serves as legal counsel to BioUtah.

#### J.P.Morgan

# Advancing breakthroughs, together

We are committed to fostering connections that drive investment and innovation in the life sciences industry.

© 2025 JPMorgan Chase & Co. All rights reserved.



WES SUNDQUIST, PH.D.
PROFESSOR & CHAIR OF
BIOCHEMISTRY, UNIVERSITY
OF UTAH

Wes Sundquist is Samuels Distinguished Professor and Chair of Biochemistry at the University of Utah. He received a BA degree in Chemistry from Carleton College, a PhD in Chemistry from MIT, and then did postdoctoral research with Sir Aaron Klug at the MRC Laboratory of Molecular Biology in Cambridge, UK. His research interests stem from the lab's work on HIV assembly and replication, and include the biochemistry and cell biology of the endosomal sorting complexes required for transport (ESCRT) pathway, and the structure, functions, and inhibition of the HIV capsid, which supported Gilead Science's development of the potent HIV prevention drug, Lenacapavir. He is a recipient of a number of awards and honors, including the Horwitz Prize for Biochemistry (Columbia University), the TIME 100 2025 list of most influential people, the Bhaumik Breakthrough Prize (Science Magazine), the World Laureate Association Prize for Life Sciences (WLA Foundation), and the Alpert Foundation Prize in Biomedicine (Harvard University).



CHARITHA TILLEKERATNE CTO, SURGICAL INNOVATIONS, GE HEALTHCARE

Charitha Tillekeratne is CTO of Surgical Innovations at GE HealthCare, leading technology strategy and product development for market-leading surgical and visualization solutions. With over 20 years of experience in medical devices and software, Charitha has built and scaled high-performing engineering teams, driven talent development, and delivered innovative products globally. He holds both bachelor's and master's degrees in Computer Science from Cornell University.



MICHELLE TARVER, M.D., PH.D. DIRECTOR, CENTER FOR DEVICES & RADIOLOGICAL HEALTH, U.S. FDA

Dr. Michelle Tarver is a visionary public health executive, board-certified in ophthalmology with a doctorate in epidemiology, who serves as the Director of the Center for Devices and Radiological Health. She has spent more than 15 years as a medical device regulator, driving strategic initiatives, conducting clinical research, and changing organizational culture. Dr. Tarver has held various leadership positions while at FDA, including the Deputy Director of the Office of Strategic Partnerships and Technology Innovation and the Program Director of Patient Science and Engagement. Over the course of her career, she has conducted laboratory-based and epidemiological studies, clinical trials, and surveys to capture patient preferences, as well as developed registries and patient-reported outcome measures. Dr. Tarver has extensive policy experience in crafting regulations, guidances, and conducting premarket and post-market reviews.



## Revealing the power of genetic science - for everyone

As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease.

#### Learn more at myriad.com

Myriad Genetics, Inc. / 322 North 2200 West, Salt Lake City, UT  $84116 \, \odot 2025$  Myriad Genetics, Inc. Myriad Genetics and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.



HARIPRASAD VANKAYALAPATI, M. PHARM., PHD. CHIEF SCIENTIFIC OFFICER, BIOLEXIS THERAPEUTICS, INC.

Hari co-founded Biolexis Therapeutics, Inc., where he serves as Chief Scientific Officer, overseeing the company's R&D strategy across metabolic, cardiometabolic, oncology, and CNS therapeutic domains. In partnership with Dr. David J. Bearss, he co-developed the proprietary MolecuLern technology platform, which underpins Biolexis' mission to discover and develop next-generation oral small-molecule therapeutics. Before founding Biolexis, Hari co-founded and led scientific functions at multiple biopharmaceutical ventures, advancing nine drug candidates into Phase I/ Il clinical evaluation. With more than two decades of experience spanning academia and industry, his career is defined by translational innovation and collaborative discovery. Hari also serves as a scientific advisor and review board member for pharmaceutical organizations and academic institutions.



LIZ WALSH COUNSEL, MAYER BROWN

Liz Walsh is counsel in Mayer Brown's Washington DC office and a member of the Public Companies & Corporate Governance and Capital Markets practices. She advises public companies on their obligations under the federal securities laws and on related corporate governance requirements. Liz also provides advice to public companies regarding compliance with SEC executive compensation disclosure requirements and Section 13 and Section 16 reporting. In addition, she advises on corporate governance matters, including advice regarding director independence, board committee structure and charters, codes of conduct, corporate governance guidelines, controls and procedures, CEO and CFO certifications, and NYSE and Nasdaq requirements.



At Renew Biotechnologies we specialize in the development and high-throughput processing of novel DNA based clinical diagnostics and research tools, building an ecosystem of innovation across our portfolio companies.

#### WASATCH.BIOLABS

Wasatch BioLabs - A leading Oxford Nanopore Technologies focused NGS sequencing service provider. As a high-throughput 20k square foot CLIA lab it processes samples in both the research and clinical settings.

| www.wasatchbiolabs.com |

### Resonant

Resonant - Unlocks new insights into neurodegenerative disease with cell type-specific cfDNA profiling from a simple blood draw, and is currently servicing and collaborating with BioPharma for research studies.

| www.resonantdx.com |



**KATHLEEN WERON**ATTORNEY,
OGLETREE DEAKINS

Kathleen Weron is a management-side employment attorney with over 30 years of experience advising and defending employers on workplace compliance, government investigations, and employment litigation. She represents employers in a wide range of federal and state statutory claims, including whistle blower actions, and provides strategic counsel on occupational safety and health issues, I-9 compliance, and workforce risk management. Kathleen has extensive experience representing employers during inspections and investigations conducted by the Department of Labor, Department of Justice, Occupational Safety and Health Administration and the Utah Labor Commission. She regularly works with business in the life sciences and manufacturing sectors to strengthen compliance practices and navigate regulatory scrutiny.



YEONG YI YIM, PH.D. DIRECTOR, KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE (KHIDI)

Dr. Yeong Yi Yim has been working for Korea Health Industry Development Institute, which was established to support the Korean health industry under the umbrella of the Ministry of Health & Welfare.





SCOTT YOUNG PARTNER, MAYER BROWN LLP

Scott has over 25 years of experience representing clients in a variety of commercial and technology-related transactions other corporate matters including technology licensing, product distribution, purchase and supply agreements, healthcare compliance, and other technology and commercial transactions. Scott works with clients in a variety of industries, including medical device, life sciences, medtech, SaaS, and other technology-based industries.






At Edwards Lifesciences we are driven by a passion for patients and dedicated to improving lives.

It's about uncovering bold advancements, innovating structural heart and critical care technologies—and dreaming big to imagine brighter futures.

It all adds up to embracing the urgency to make a difference where it matters most. It's our mission for life ...

... and life is now.






© 2022 Edwards Lifesciences Corporation. All rights reserved. PP--US-1612 v4.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com







#### **ON-SITE & VIRTUAL EXHIBITORS**

#### VISIT THE BOOTH OF THE EXHIBITORS LISTED BELOW







































































#### CHECK OUT THE VIRTUAL BOOTHS OF OUR ONLINE EXHIBITORS

In addition to our on-site exhibitors, please visit our virtual exhibit hall that includes many of our on-site exhibitors as well.



Use this QR code to view the virtual exhibitors.



# PARTNER WITH UTAH'S FLAGSHIP LIFE SCIENCES INSTITUTION

#### **Driving Innovation and Impact**

The University of Utah offers flexible partnerships—sponsored research, joint ventures, and licensing agreements—translating innovations into real-world solutions. Our Technology Licensing Office connects you with cutting-edge research for efficient commercialization.



\$781.9M



530
DISCLOSURES



27
LICENSING DEALS



963,000+
sq. ft. dedicated to research



43
U.S. PATENTS ISSUED

\*FY25 Metrics



NEW STARTUPS









#### **BOARD OF DIRECTORS**

CHAIR
MARK PAUL
UNIVERSITY OF UTAH

VICE CHAIR ERIN BARRY MERIT MEDICAL SYSTEMS

PAST CHAIR
MYLES GREENBERG
INCARDA THERAPEUTICS

JARED BAUER SEEK LABS

DAVID BEARSS HALIA THERAPEUTICS

JONATHAN CARTER EDWARDS LIFESCIENCES

JIM FITZGERALD ATL TECHNOLOGY

TRACY GEORGE ARUP LABORATORIES

ANDREW HEMMERT BIOMÉRIEUX LINCOLN HOWELL AMPLĒO

CHRIS LOWE NUSANO

JEFF LYON
INTERMOUNTAIN HEALTH

HAVEN McCALL BLUE SKY BIO LABS

JAY MUSE PIPER ACCESS

MICHAEL OLSON ZIONS BANK PHIL PRENTICE
BECTON DICKINSON

RANDY RASMUSSEN R!P BIOSCIENCES

JOSH WALKER NOMI HEALTH

LEGAL COUNSEL JACEY SKINNER BALLARD SPAHR LLP

#### **ELITE** BIOUTAH MEMBERS

#### **LEGACY MEMBERS**





#### PLATINUM MEMBERS

















#### **GOLD MEMBERS**













#### SILVER MEMBERS

#### Ballard Spahr



J.P.Morgan





WILSON SONSINI

#### **BRONZE MEMBERS**

















































**ZIONS BANK** 

## stryker

We improve

# lives

Customers and patients are at the heart of everything we do.

We're a driven company where people work with passion, purpose and integrity to deliver remarkable, innovative products for customers and patients.

Find out more about how you can make a difference at careers.stryker.com



